Percheron Therapeutics Limited (ASX:PER)

Percheron Therapeutics Revenue

In the fiscal year ending June 30, 2026, Percheron Therapeutics had annual revenue of 843.60K AUD, down -53.16%. Percheron Therapeutics had revenue of 755.19K in the half year ending June 30, 2026, a decrease of -57.29%. That makes Percheron Therapeutics the 44,314th largest company in the world by revenue and 1,018th in Australia.

• Revenue: 843.60K
• Revenue Growth: -53.16%
• P/S Ratio: 9.40
• Revenue / Employee: 105.45K
• Employees: 8
• Market Cap: 7.93M

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• ATL1102 351.93K 41.7%
• Hmbd-002 344.41K 40.8%
• Unallocated 147.26K 17.5%

Fiscal year ended Jun 30, 2026 See the full Percheron Therapeutics breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2026	843.60K	-957.46K	-53.16%
Jun 30, 2025	1.80M	-1.17M	-39.32%
Jun 30, 2024	2.97M	1.00M	51.07%
Jun 30, 2023	1.96M	186.87K	10.51%
Jun 30, 2022	1.78M	1.20M	207.72%

Data Source: S&P Global Market Intelligence Last updated: Aug 19, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 20, 2026

Data Sources Report a data error